Orexo AB´s sustainability work ranked among top 5% by EcoVadis
UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provider of business sustainability ratings. The highly revered award places the company in the top 5 percent of all 70,000 businesses worldwide that are reviewed by EcoVadis each year.
This top rating is based on Orexo AB's first year of reporting to EcoVadis and mainly includes sustainability data related to the business in Sweden, covering Group headquarters functions, R&D, Regulatory Affairs, Quality & She, and Supply Chain.
It showcases the outcome of dedicated sustainability activities undertaken over the last several years across social, environmental and governance areas of Orexo AB. And it shows how the employees and partners are working together to achieve successes across four areas: Environment, Labor and Human Rights, Ethics and Sustainable Procurement.
Nikolaj Sørensen, President and CEO, of Orexo, said, "Achieving this rating is a privilege and we will continue setting ambitious goals in our active pursuit of an even more sustainable and inclusive future for everyone. This is central to our values-based approach to growth and underpins optimal outcomes for patients, investors, the company and society more broadly."
Contacts:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
ir@orexo.com
+46 (0)18 780 88 00
Related links
EcoVadis: https://ecovadis.com/
Sustainability at Orexo: https://orexo.com/sustainability/
About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
The information was submitted for publication at 8 a.m. CET, on July 10, 2024.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Orexo_PR_Orexo AB sustainability work ranked among top 5 percent by EcoVadis_July 10 2024 | |
4013283_0.png |
View original content:https://www.prnewswire.co.uk/news-releases/orexo-abs-sustainability-work-ranked-among-top-5-by-ecovadis-302193098.html
Upcoming Life Sciences Events
- December 2024
- Pre-JPM Partnering Week
- Spectrum of Stem Cell Neuronal Models and Their Purpose Fit
- January 2025
- San Francisco: 8th Annual Neuroscience Innovation Forum